Q-omics provides the consensus-scored ATXN7L3 profile across patient tissues and cancer cell-line models. ATXN7L3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ATXN7L3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ATXN7L3 protein abundance shows 32,221 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where ATXN7L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATXN7L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATXN7L3 survival associations across molecular data types. ATXN7L3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATXN7L3 RNA expression–survival associations across cancer types. High ATXN7L3 expression shows unfavorable associations in ACC, LIHC, KIRP, UVM and CESC, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ATXN7L3 RNA expression.
This table summarizes ATXN7L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ATXN7L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATXN7L3 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, LUAD, LUSC and STAD. The HNSC box plot shows higher ATXN7L3 RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with ATXN7L3 in patient tissues and cancer cell lines. In patient samples, ATXN7L3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATXN7L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
